Life After Brexit - IP Developments in UK and Europe (RECORDING)

Caelia Bryn-Jacobsen's over 20 years’ experience in the patent profession is grounded in her strong technical background.  Following her physics degree at Oxford, Caelia went on to research her doctorate by studying magnetic interactions at low temperatures. Caelia’s patent portfolio has evolved to reflect her passion for physics, and covers a range of technologies including aeronautics and aerospace, energy and power management, cooling systems, telecoms, thin film technology, and software.

From strategic drafting to focused prosecution, Caelia’s extensive experience enables her to provide clear, commercially astute advice throughout every stage of the patenting process. Caelia specialises in contentious post grant proceedings, with her considerable knowledge in this area leading to a reputation for successfully defending patents in EPO opposition and appeals work.  
 
Caelia enjoys advising a diverse client base that encompasses multinational companies, university spin outs, and direct clients. For all of these, Caelia’s emphasis is upon developing IP strategies that allow clients maximise their existing and potential IP assets in the context of their business needs.
 
Caelia chairs the Chartered Institute of Patent Attorney’s Professional Development Working Group, and is also a member of its Steering Committee, Educational Committee, and UPC Task Force, as well as IP Ability.

Matthew Georgiou is a Partner in the Life Sciences group. Matthew spends the majority of his time counselling clients in the pharmaceutical sector on strategies for maintaining market exclusivity in Europe. In this role he has assisted some of the world’s largest drug companies in protecting their intellectual property. At the core of Matthew’s practice is his experience representing clients before the European Patent Office in ex parte examination proceedings and inter partes opposition and appeal proceedings. He has handled complex multiparty opposition proceedings (in attack and defense) relating to a variety of commercial respiratory, oncology and analgesic products and his endeavors for clients have taken him all the way to the EPO’s Enlarged Board of Appeal.

Matthew is the Vice Chair of the IPO’s European Practice Committee. He is actively involved in committee work and regularly speaks at IPO events.

Leythem Wall is a European and UK patent attorney and litigator specializing in the chemical, consumer products, energy, material, mechanical, medical and pharmaceutical sectors. Prior to founding Oxon IP, he was a Partner in major European and US Intellectual Property law firms, and before then in-house patent counsel for some of the world’s largest US and European multinationals.

He regularly represents clients in Opposition and Appeal proceedings before the European Patent Office (EPO) as lead counsel in a wide variety of technical areas. He has won numerous defensive and offensive oppositions, including multi-party proceedings, and successful coordination with disputes in multiple jurisdictions such as UK, Germany, US, China, Japan, Korea, and India.

A frequent author and lecturer on patent law, Leythem has had numerous articles published in legal journals and spoken at international programs and conferences in Europe, USA and Asia, as well as before Fortune 500 companies.

Leythem is listed as a Patent Star by MIP, a WIPR Leader and appears on both the IAM 1000 (The World’s Leading Patent Professionals) and the IAM 300 (The World’s Leading IP Strategists and Global Leaders), specifically cited for his EPO Opposition experience.